Loading stock data…
APLS
$40.96+0.01 (+0.02%)
Market ClosedLast close May 1
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apellis Pharmaceuticals, Inc. in the Healthcare sector is trading at $40.96. The stock is currently near its 52-week high of $41.00, remaining 63.8% above its 200-day moving average. Technical signals show neutral RSI of 70 and bearish MACD signal, explaining why APLS maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$40.96
Potential Downside
97.5%
Whystock Fair Value$1.02
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Hold
Mean target$40.93-0.1%
Range$40.00 – $41.00
Fundamentals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
227.17
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.64%
Volume
Today's trading volume
1.68M
Recent News
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance
Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using the AntiClastic ASO Platform. These moves expand Biogen's presence in targeted therapies and antisense technologies beyond previously discussed valuation topics. For investors watching NasdaqGS:BIIB, these transactions come with the stock trading at around $177.35 and a 1 year return of 49.5%...
Tesla upgraded, AppLovin initiated: Wall Street's top analyst calls
Tesla upgraded, AppLovin initiated: Wall Street's top analyst calls